Free Design Audit Available - Click Here for Details

FDA expands approval for Boston Scientific spinal cord stim to include chronic back pain without prior back surgery

Boston Scientific (NYSE: BSX)+ announced today that the FDA approved an expanded indication for its WaveWriter spinal cord stimulation (SCS) systems.

The indication covers chronic low back and leg pain in people without prior back surgery — called non-surgical back pain (NSBP).

Boston Scientific says first-line treatment for people with chronic back pain tends to have limitations. Conventional medical management like physical therapy and medication tend to prove less effective for many people. Effective chronic pain management may lead to improved quality of life and reduced opioid use.

In a news release, Dr. James North of the Carolinas Pain Institute said this expanded indication helps people with limited treatment options. North also served as the principal investigator for the SOLIS trial of the technology for treating NSBP.

Sign up for Blog Updates